MARKET OUTLOOK 
Asthma pharmacotherapy has two main goals: to address underlying airways inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals: maintenance therapy (, a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort) and rescue therapy (, a SABA, such as albuterol); and most asthma patients will receive more than one drug to treat their condition. While there are multiple well-established agents available for both maintenance and rescue treatment, over the past two years, the asthma treatment landscape has witnessed the approval of the first once-daily LABA/ICS (, GSK’s Breo), the first LAMA (, Boehringer Ingelheim’s Spiriva), and the first—in over ten years—biologic (, GSK’s Nucala). The availability of these agents has helped to expand physicians' treatment armamentarium and fuel increasing competition in the asthma market. 

PRODUCT DESCRIPTION 
Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share. 

Questions Answered in This Report:

    • What patient share do key therapies and brands garner by line of therapy in newly diagnosed asthma patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed asthma patients? 
    • How have newer inhaled asthma therapies, such as Breo and Spiriva, been integrated into the treatment algorithm? 
    • What proportion of asthma patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis? 
    • What percentage of asthma patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies? 
    • What are the product-level compliance and persistency rates among drug-treated patients with asthma? 

Related Reports

Asthma | Emerging Therapies | Dupixent (Dupilumab) (US) Wave 3

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of...

View Details

Asthma | Landscape & Forecast | Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim&rsquo...

View Details

Asthma | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details